Evaluation of L-Alpha-Acetylmethadol (LAAM) in Methadone Patients - 5
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on August 03, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Opioid-Related Disorders; Substance-Related Disorders
Intervention: LAAM (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Charles O'Brien, M.D., Ph.D., Principal Investigator, Affiliation: PDVAMC Treatment Research Center
Summary
The purpose of this study is to determine the pharmacokinetics of L-alpha-acetylmethadol (LAAM) in adults transferred from methadone maintenance treatment for opiate dependence.
Clinical Details
Official title:
Pharmacokinetics of LAAM in Methadone Patients
Study design: Interventional, Treatment
Eligibility
Gender(s): Both.
Criteria:
Please contact site for information.
Locations and Contacts
University of Pennsylvania, Philadelphia, Pennsylvania 19104 6178, United States
Additional Information
Starting date:
June 1991
Last updated: June 23, 2005
|
